AnGes AI Stock Analysis
Want to see JP:4563 full AI Analyst Report?
AnGes (4563) AI Stock Analysis
AnGes
(TSE/TYO:4563)
The score is held down primarily by weak financial performance driven by ongoing losses and significant cash burn, despite improving revenue momentum. Technicals also weigh negatively given the strong downtrend across moving averages and weak momentum, even though the stock appears oversold. Valuation is neutral-to-cautious because the negative P/E reflects continuing losses and dividend support is not indicated.
AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 143.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.86M
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 0.75
- Revenue Growth
- 35.28%
- EPS Growth
- 90.12%
- Country
- Japan
- Employees
- 56
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AnGes Business Overview & Revenue Model
Company Description
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmi...
How the Company Makes Money
AnGes primarily makes money by monetizing its biotechnology pipeline and approved products through a combination of product-related revenue and collaboration-based income. Revenue can include (1) sales of any commercialized products the company has o...
AnGes Financial Statement Overview
Summary
Revenue growth has accelerated meaningfully, but the fundamentals remain weak: persistent large operating losses and negative net income continue, and operating/free cash flow are deeply negative, indicating ongoing cash burn and elevated funding risk. The balance sheet has low leverage, but declining equity/assets suggests continued erosion from losses.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.90M | 874.12M | 643.00M | 152.99M | 67.06M | 64.15M |
| Gross Profit | 398.00M | 320.38M | 247.00M | 19.45M | -26.83M | 7.43M |
| EBITDA | -5.51B | -5.09B | -5.74B | -8.86B | -13.41B | -13.21B |
| Net Income | -3.87B | -5.12B | -28.13B | -7.44B | -14.71B | -13.68B |
Balance Sheet | ||||||
| Total Assets | 3.66B | 5.41B | 4.67B | 28.89B | 38.82B | 45.46B |
| Cash, Cash Equivalents and Short-Term Investments | 296.72M | 1.88B | 1.71B | 4.16B | 11.04B | 17.90B |
| Total Debt | 723.78M | 54.37M | 272.45M | 362.68M | 1.16B | 0 |
| Total Liabilities | 3.45B | 2.33B | 2.51B | 2.79B | 8.40B | 6.82B |
| Stockholders Equity | 205.68M | 3.08B | 2.16B | 26.10B | 30.43B | 38.63B |
Cash Flow | ||||||
| Free Cash Flow | -1.38B | -5.76B | -6.69B | -8.84B | -11.23B | -11.46B |
| Operating Cash Flow | -1.38B | -5.75B | -6.61B | -8.74B | -11.21B | -11.38B |
| Investing Cash Flow | -80.00K | 18.48M | -130.80M | -356.65M | -97.14M | -154.87M |
| Financing Cash Flow | 567.54M | 5.90B | 4.20B | 2.04B | 3.57B | 17.38B |
AnGes Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Negative. The current price of 27.00 is below the 20-day moving average (MA) of 28.55, below the 50-day MA of 33.50, and below the 200-day MA of 47.87, indicating a bearish trend. The MACD of -2.29 indicates Negative momentum. The RSI at 36.98 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4563.
AnGes Peers Comparison
Overall Rating
JP:456563Neutral
JP:458855Neutral
JP:459349Neutral- JP:456344Neutral
JP:777442Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4565 | 63Neutral | JPY 166.34B | -30.09 | -8.51% | ― | 23.72% | 12.48% |
| JP:4588 | 55Neutral | JPY 221.84B | -145.74 | ― | ― | 1748.97% | 35.11% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 49Neutral | JPY 32.26B | 48.59 | ― | ― | -47.32% | ― |
| JP:4563 | 44Neutral | JPY 10.72B | -2.83 | -163.39% | ― | 35.28% | 90.12% |
| JP:7774 | 42Neutral | JPY 27.45B | -75.71 | ― | ― | 17.05% | 10.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4563 | AnGes | 27.00 | -50.00 | -64.94% | |
| JP:4565 | Sosei Group Corporation | 1811.00 | 962.00 | 113.31% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7900.00 | 6842.00 | 646.69% | |
| JP:4593 | Healios KK | 241.00 | -220.00 | -47.72% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 680.00 | 185.00 | 37.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026